What is the recommended dose of bisacodyl (stimulant laxative) for pediatric (peds) patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Bisacodyl Dosing for Pediatric Patients

For pediatric patients, bisacodyl dosing is age-based: children 6 to under 12 years receive 5 mg once daily (orally or rectally), and children 12 years and older receive 10 mg once daily, with use under 6 years requiring physician consultation. 1

Age-Specific Dosing Guidelines

Children Under 6 Years

  • Bisacodyl use requires physician consultation and individualized dosing in this age group 1
  • Safety and efficacy data are limited for children under 6 years 1

Children 6 to Under 12 Years

  • Oral or rectal dose: 5 mg once daily 1
  • For rectal suppositories, use half of a 10 mg suppository 1
  • This represents the standard FDA-approved dosing for this age range 1

Adolescents 12 Years and Older

  • Oral or rectal dose: 10 mg once daily 1
  • Adult dosing applies to this age group 1
  • Maximum daily dose should not exceed 10 mg 2

Clinical Context and Evidence

Long-Term Use in Refractory Constipation

  • In pediatric patients with functional constipation refractory to conventional therapy (osmotic laxatives), bisacodyl at a median dose of 5 mg/day for a median duration of 14 months proved effective and well-tolerated 3
  • 57% of patients achieved successful response (≥3 bowel movements per week), with bowel movement frequency doubling from 2 to 4 per week 3
  • 55% of successfully treated patients were weaned off bisacodyl after a median of 18 months 3
  • Side effects occurred in only 9% of patients during long-term use 3

Bowel Preparation Protocols

  • For colonoscopy preparation in children aged 30 months to 12 years, a protocol using 5 mg bisacodyl at noon (with an additional 5 mg in the evening for children >5 years) combined with fleet enemas achieved 95% good-to-excellent bowel preparation 4
  • One-day preparation with PEG 3350 (4 g/kg/day) plus bisacodyl showed similar tolerance and safety to two-day preparation protocols 5

Important Clinical Considerations

Timing and Administration

  • Oral tablets have an onset of action of 6-12 hours 2
  • For rectal suppositories, insert with pointed end first and retain for 15-20 minutes 1
  • If suppository seems soft, refrigerate briefly before use 1

Common Pitfalls to Avoid

  • Do not exceed recommended daily doses, as this increases risk of diarrhea and electrolyte imbalances 2
  • Bisacodyl is recommended for short-term use or rescue therapy rather than first-line long-term treatment 2
  • Common adverse effects include diarrhea (53.4% vs 1.7% placebo) and abdominal pain (24.7% vs 2.5% placebo) 2

Contraindications

  • Avoid in patients with ileus, intestinal obstruction, severe dehydration, or acute inflammatory bowel conditions 2

Role in Treatment Algorithm

  • Bisacodyl should typically be used as rescue therapy after osmotic laxatives (such as PEG 3350 or lactulose) have been tried as first-line agents 3
  • However, in refractory cases, regular long-term use can be considered with appropriate monitoring 3
  • When transitioning away from chronic bisacodyl use, gradually taper while adding osmotic laxatives over 2-3 months 6

References

Guideline

Bisacodyl Dosage and Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Restoring Natural Bowel Function After Long-term Stimulant Laxative Use

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.